Karyopharm Therapeutics (STU:25K0) Cyclically Adjusted Book per Share: €11.52 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:25K0 Karyopharm Therapeutics Inc STU:25K0
60 GF Score
Price €6.15
GF Value €5.22
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Karyopharm Therapeutics Cyclically Adjusted Book per Share?

Karyopharm Therapeutics STU:25K0 -10.87% 60 Cyclically Adjusted Book per Share is €11.52 as of Mar. 2026. GuruFocus rates STU:25K0 with a GF Score™ of 60/100 and a GF Value™ of €5.22 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Karyopharm Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €-10.193. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €11.52 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Karyopharm Therapeutics's average Cyclically Adjusted Book Growth Rate was -50.20% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -30.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Karyopharm Therapeutics was -30.00% per year. The lowest was -30.00% per year. And the median was -30.00% per year.

As of today (2026-07-24), Karyopharm Therapeutics's current stock price is €6.15. Karyopharm Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €11.52. Karyopharm Therapeutics's Cyclically Adjusted PB Ratio of today is 0.53.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Karyopharm Therapeutics was 2.58. The lowest was 0.13. And the median was 0.42.


Karyopharm Therapeutics  (STU:25K0) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Karyopharm Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=6.15/11.52
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Karyopharm Therapeutics was 2.58. The lowest was 0.13. And the median was 0.42.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Karyopharm Therapeutics Cyclically Adjusted Book per Share Related Terms


Karyopharm Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Karyopharm Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Karyopharm Therapeutics Cyclically Adjusted Book per Share Chart

Karyopharm Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 37.16 39.61 29.34 13.29

Karyopharm Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.11 18.87 15.36 13.29 11.52

STU:25K0 vs CHRS, TARA, CNTN: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Karyopharm Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karyopharm Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Karyopharm Therapeutics's Cyclically Adjusted PB Ratio falls into.


STU:25K0
60GF Score
Karyopharm Therapeutics Inc STU:25K0
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Karyopharm Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Karyopharm Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-10.193/330.2130*330.2130
=-10.193

Current CPI (Mar. 2026) = 330.2130.

Karyopharm Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 56.971 241.018 78.055
201609 56.169 241.428 76.825
201612 55.068 241.432 75.318
201703 46.319 243.801 62.736
201706 47.223 244.955 63.659
201709 37.674 246.819 50.403
201712 33.131 246.524 44.378
201803 23.399 249.554 30.962
201806 45.309 251.989 59.374
201809 36.255 252.439 47.425
201812 39.706 251.233 52.188
201903 26.450 254.202 34.359
201906 17.959 256.143 23.152
201909 13.005 256.759 16.725
201912 10.279 256.974 13.209
202003 30.856 258.115 39.475
202006 23.566 257.797 30.186
202009 14.509 260.280 18.407
202012 8.431 260.474 10.688
202103 -6.654 264.877 -8.295
202106 -13.740 271.696 -16.699
202109 -21.276 274.310 -25.612
202112 -13.963 278.802 -16.538
202203 -14.247 287.504 -16.363
202206 -20.687 296.311 -23.054
202209 -26.228 296.808 -29.180
202212 -2.083 296.797 -2.318
202303 -5.553 301.836 -6.075
202306 -8.627 305.109 -9.337
202309 -12.321 307.789 -13.219
202312 -16.303 306.746 -17.550
202403 -20.020 312.332 -21.166
202406 -14.774 314.175 -15.528
202409 -17.218 315.301 -18.032
202412 -21.116 315.605 -22.093
202503 -22.227 319.799 -22.951
202506 -23.956 322.561 -24.524
202509 -26.363 324.800 -26.802
202512 -13.662 324.054 -13.922
202603 -10.193 330.213 -10.193

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €11.52 mean?
Karyopharm Therapeutics (STU:25K0) has a Cyclically Adjusted Book per Share of €11.52 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Karyopharm Therapeutics and its competitors.
Is Karyopharm Therapeutics' Cyclically Adjusted Book per Share too high?
Karyopharm Therapeutics' current Cyclically Adjusted Book per Share is €11.52. Overall, Karyopharm Therapeutics has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Karyopharm Therapeutics' Cyclically Adjusted Book per Share compare to CHRS and TARA?
Karyopharm Therapeutics' Cyclically Adjusted Book per Share of €11.52 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Karyopharm Therapeutics and its competitors. Karyopharm Therapeutics's current Cyclically Adjusted Book per Share is €11.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Karyopharm Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Karyopharm Therapeutics (STU:25K0) is currently considered Modestly Overvalued. The stock's GF Value™ is €5.22, compared to a current price of €6.15 — trading 17.8% above its estimated fair value. The current Cyclically Adjusted Book per Share is €11.52. Karyopharm Therapeutics' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Karyopharm Therapeutics (STU:25K0), the current Cyclically Adjusted Book per Share is €11.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Karyopharm Therapeutics (STU:25K0) Overvalued in 2026?

Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be overvalued. The current stock price of €6.15 is trading 17.8% above its estimated GF Value™ of €5.22. GuruFocus considers Karyopharm Therapeutics to be Modestly Overvalued.

Key valuation signals for STU:25K0:

  • Cyclically Adjusted Book per Share: €11.52
  • GF Value™: €5.22 vs. price of €6.15 (17.8% above fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the STU:25K0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Karyopharm Therapeutics Business Description

Other Exchanges KPTI:USA
Address 85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
60GF Score

Get the complete analysis for STU:25K0

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.15
Price
€5.22
GF Value